von der Leyen HE - Search Results

1

Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene.

von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. von der Leyen HE, et al. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1137-41. doi: 10.1073/pnas.92.4.1137. Proc Natl Acad Sci U S A. 1995. PMID: 7532305 Free PMC article.

2

[Experimental approaches for gene therapy modification of vascular remodeling].

von der Leyen HE, Dzau VJ. von der Leyen HE, et al. Z Kardiol. 1995 Oct;84(10):791-7. Z Kardiol. 1995. PMID: 7502565 Review. German.

3

Gene inhibition and gene augmentation for the treatment of vascular proliferative disorders.

von der Leyen HE, Mann MJ, Dzau VJ. von der Leyen HE, et al. Semin Interv Cardiol. 1996 Sep;1(3):209-14. Semin Interv Cardiol. 1996. PMID: 9552513 Review.

4

Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle.

Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindade PT, Cooke JP, Hunt SA, Billingham ME, Valantine HA, Fowler MB. Lewis NP, et al. Circulation. 1996 Feb 15;93(4):720-9. doi: 10.1161/01.cir.93.4.720. Circulation. 1996. PMID: 8641001

5

Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy.

Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Morishita R, et al. Trans Assoc Am Physicians. 1993;106:54-61. Trans Assoc Am Physicians. 1993. PMID: 8036745 No abstract available.

6

Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.

Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Morishita R, et al. J Clin Invest. 1994 Apr;93(4):1458-64. doi: 10.1172/JCI117123. J Clin Invest. 1994. PMID: 8163650 Free PMC article.

7

Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts.

Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Cooke JP, Buitrago R, Kernoff R, Dzau VJ. Mann MJ, et al. Among authors: von der leyen he. J Clin Invest. 1997 Mar 15;99(6):1295-301. doi: 10.1172/JCI119288. J Clin Invest. 1997. PMID: 9077539 Free PMC article.

8

The concept and potentials of cardiovascular gene therapy.

Dzau VJ, von der Leyen HE, Morishita R. Dzau VJ, et al. Among authors: von der leyen he. Indian Heart J. 1998 Jan-Feb;50(1):23-33. Indian Heart J. 1998. PMID: 9583283 Review. No abstract available.

9

A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer.

von der Leyen HE, Braun-Dullaeus R, Mann MJ, Zhang L, Niebauer J, Dzau VJ. von der Leyen HE, et al. Hum Gene Ther. 1999 Sep 20;10(14):2355-64. doi: 10.1089/10430349950017004. Hum Gene Ther. 1999. PMID: 10515455

10

Therapeutic potential of nitric oxide synthase gene manipulation.

von der Leyen HE, Dzau VJ. von der Leyen HE, et al. Circulation. 2001 Jun 5;103(22):2760-5. doi: 10.1161/01.cir.103.22.2760. Circulation. 2001. PMID: 11390349 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters